The Healthcare Specialist
Driven by Passion.
Powered by Science.
Passion is our driver and science is our foundation. At Rhenman & Partners we only invest in the healthcare sector and our investment process takes both scientific and financial aspects into consideration. The portfolio managers are supported in their investment decisions through close collaboration with our Scientific Advisory Board, which consists of experts within different medical fields.
Rhenman Healthcare Equity L/S is an AIF which is available to retail investors in Sweden and Finland only, and it is registered for professional investors only in Belgium, Finland, the Netherlands, Italy, Sweden, the United Kingdom, Singapore with restricted scheme offered to accredited investors only and Switzerland (distributed without FINMA registration.)
*As of XX-XX-XXXX (IC1 EUR)
Rhenman Healthcare Equity L/S (RHE L/S)
| FUND CLASS | NAV | DEVELOPMENT 1 MONTH | THIS YEAR | SINCE FUND START | START DATE |
| IC1 (EUR) | 815.93 | 1.94% | -10.98% | 715.93% | 2009-06-22 |
| IC3 (EUR) | 1057.91 | 2.01% | -10.48% | 957.91% | 2009-07-31 |
| IC2 (SEK) | 656.61 | 1.75% | -13.70% | 556.61% | 2012-12-31 |
| ID1 (SEK) Distributing | 358.22 | 1.70% | -17.76% | 258.22% | 2012-04-30 |
| IC1 (USD) | 216.52 | 2.33% | 0.97% | 116.52% | 2015-01-31 |
| RC1 (EUR) | 691.57 | 1.89% | -11.34% | 591.57% | 2010-08-31 |
| RC1 (SEK) | 750.02 | 1.65% | -14.37% | 650.02% | 2009-06-22 |
| RC2 (SEK) | 805.13 | 1.70% | -14.05% | 705.13% | 2009-06-22 |
Important information: Past performance is no guarantee of future returns. The money invested in the fund can both increase and decrease in value and it is not certain that investors will get back the entire invested capital.
Rhenman Healthcare Equity L/S
Important information: Past performance is no guarantee of future returns. The money invested in the fund can both increase and decrease in value and it is not certain that investors will get back the entire invested capital.
Det här är Rhenman & Partners
Who we are
A team of healthcare specialists.
One of the key drivers of our success is our team of engaged portfolio managers, each specializing in a specific sub-sector - pharmaceuticals, biotech, medical technology, and healthcare services.
Their in-depth expertise is complemented by ongoing access to our Scientific Advisory Board, enabling them to identify emerging trends, breakthrough innovation and high-potential companies at an early stage.
The science behind
our portfolio managers.
Our dedicated Scientific Advisory Board consists of eminent medical experts, each with their own broad network of medical researchers and specialists around the world. This collaborative process provides invaluable insights for our investment decisions and enables us to take a higher, yet more balanced level of risk.
Our unique scientific
working method.
Our way of working is built upon a well-tried, quality-assured investment strategy.
Portfolio managers with expert knowledge
Our portfolio managers have a deep level of expertise within the sub-sectors: pharmaceuticals, biotech, medical technology and healthcare services.
Backed by our Scientific Advisory Board
Förvaltarna stämmer regelbundet av sina analyser med det vetenskapliga rådet, som består av välrenommerade medicinska experter med forskarkollegor världen över.
A mandate to take on risk
Thanks to our scientific method, our in-depth analysis, and our more flexible investment mandate, we are able to take on a higher, yet more balanced level of risk.
A sector with potential
The healthcare sector is characterized by research and innovation and is driven by megatrends, such as, population growth, higher living standards and digitalization.
Responsible investments
Together, we make the world a little healthier
By investing in healthcare, innovations within medical research receive support which in turn helps make the world a little healthier and improves people’s quality of life.
News
All
Direkt
Finwire
Uncategorized
Rhenman & Partners
Subscribe to ‘News’
Read interesting news, the portfolio managers’ insights and the latest developments in the fund.